Literature DB >> 21930603

The GABRA6 mutation, R46W, associated with childhood absence epilepsy, alters 6β22 and 6β2 GABA(A) receptor channel gating and expression.

Ciria C Hernandez1, Katharine N Gurba, Ningning Hu, Robert L Macdonald.   

Abstract

A GABA(A) receptor α6 subunit mutation, R46W, was identified as a susceptibility gene that may contribute to the pathogenesis of childhood absence epilepsy (CAE), but the molecular basis for alteration of GABA(A) receptor function is unclear. The R46W mutation is located in a region homologous to a GABA(A) receptor γ2 subunit missense mutation, R82Q, that is associated with CAE and febrile seizures in humans. To determine how this mutation reduces GABAergic inhibition, we expressed wild-type (α6β2γ2L and α6β2δ) and mutant (α6(R46W)β2γ2L and α6(R46W)β2δ) receptors in HEK 293T cells and characterize their whole-cell and single-channel currents, and surface and total levels. We demonstrated that gating and assembly of both α6(R46W)β2γ2L and α6(R46W)β2δ receptors were impaired. Compared to wild-type currents, α6(R46W)β2γ2L and α6(R46W)β2δ receptors had a reduced current density, α6(R46W)β2γ2L currents desensitized to a greater extent and deactivated at a slower rate, α6(R46W)β2δ receptors did not desensitize but deactivated faster and both α6(R46W)β2γ2L and α6(R46W)β2δ single-channel current mean open times and burst durations were reduced. Surface levels of coexpressed α6(R46W), β2 and δ, but not γ2L, subunits were decreased. 'Heterozygous' coexpression of α6(R46W) and α6 subunits with β2 and γ2L subunits produced intermediate macroscopic current amplitudes by increasing incorporation of wild-type and decreasing incorporation of mutant subunits into receptors trafficked to the surface. Finally, these findings suggest that similar to the γ2(R82Q) mutation, the CAE-associated α6(R46W) mutation could cause neuronal disinhibition and thus increase susceptibility to generalized seizures through a reduction of αβγ and αβδ receptor function and expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21930603      PMCID: PMC3249055          DOI: 10.1113/jphysiol.2011.218883

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  47 in total

1.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution.

Authors:  Nigel Unwin
Journal:  J Mol Biol       Date:  2005-01-25       Impact factor: 5.469

2.  The epilepsy mutation, gamma2(R43Q) disrupts a highly conserved inter-subunit contact site, perturbing the biogenesis of GABAA receptors.

Authors:  Tim G Hales; Haiyan Tang; Karen A Bollan; Sara J Johnson; Dale P King; Neil A McDonald; Aixin Cheng; Christopher N Connolly
Journal:  Mol Cell Neurosci       Date:  2005-05       Impact factor: 4.314

3.  Comparative models of GABAA receptor extracellular and transmembrane domains: important insights in pharmacology and function.

Authors:  Margot Ernst; Stefan Bruckner; Stefan Boresch; Werner Sieghart
Journal:  Mol Pharmacol       Date:  2005-08-15       Impact factor: 4.436

Review 4.  Gating of nicotinic ACh receptors; new insights into structural transitions triggered by agonist binding that induce channel opening.

Authors:  Elaine A Gay; Jerrel L Yakel
Journal:  J Physiol       Date:  2007-09-06       Impact factor: 5.182

Review 5.  Recent advances in Cys-loop receptor structure and function.

Authors:  Steven M Sine; Andrew G Engel
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

Review 6.  Genetics of idiopathic epilepsies.

Authors:  Shinichi Hirose; Akihisa Mitsudome; Motohiro Okada; Sunao Kaneko
Journal:  Epilepsia       Date:  2005       Impact factor: 5.864

7.  Gene knockout of the alpha6 subunit of the gamma-aminobutyric acid type A receptor: lack of effect on responses to ethanol, pentobarbital, and general anesthetics.

Authors:  G E Homanics; C Ferguson; J J Quinlan; J Daggett; K Snyder; C Lagenaur; Z P Mi; X H Wang; D R Grayson; L L Firestone
Journal:  Mol Pharmacol       Date:  1997-04       Impact factor: 4.436

8.  Initial coupling of binding to gating mediated by conserved residues in the muscle nicotinic receptor.

Authors:  Nuriya Mukhtasimova; Chris Free; Steven M Sine
Journal:  J Gen Physiol       Date:  2005-06-13       Impact factor: 4.086

9.  Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy.

Authors:  Miyabi Tanaka; Richard W Olsen; Marco T Medina; Emily Schwartz; Maria Elisa Alonso; Reyna M Duron; Ramon Castro-Ortega; Iris E Martinez-Juarez; Ignacio Pascual-Castroviejo; Jesus Machado-Salas; Rene Silva; Julia N Bailey; Dongsheng Bai; Adriana Ochoa; Aurelio Jara-Prado; Gregorio Pineda; Robert L Macdonald; Antonio V Delgado-Escueta
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

10.  Crystal structure of the extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A resolution.

Authors:  Cosma D Dellisanti; Yun Yao; James C Stroud; Zuo-Zhong Wang; Lin Chen
Journal:  Nat Neurosci       Date:  2007-07-22       Impact factor: 24.884

View more
  24 in total

1.  GABRB3 mutation, G32R, associated with childhood absence epilepsy alters α1β3γ2L γ-aminobutyric acid type A (GABAA) receptor expression and channel gating.

Authors:  Katharine N Gurba; Ciria C Hernandez; Ningning Hu; Robert L Macdonald
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

2.  Dodecyl maltopyranoside enabled purification of active human GABA type A receptors for deep and direct proteomic sequencing.

Authors:  Xi Zhang; Keith W Miller
Journal:  Mol Cell Proteomics       Date:  2014-12-03       Impact factor: 5.911

3.  A novel variant in GABRB2 associated with intellectual disability and epilepsy.

Authors:  Siddharth Srivastava; Julie Cohen; Jonathan Pevsner; Swaroop Aradhya; Dianalee McKnight; Elizabeth Butler; Michael Johnston; Ali Fatemi
Journal:  Am J Med Genet A       Date:  2014-08-13       Impact factor: 2.802

4.  Three epilepsy-associated GABRG2 missense mutations at the γ+/β- interface disrupt GABAA receptor assembly and trafficking by similar mechanisms but to different extents.

Authors:  Xuan Huang; Ciria C Hernandez; Ningning Hu; Robert L Macdonald
Journal:  Neurobiol Dis       Date:  2014-05-04       Impact factor: 5.996

Review 5.  Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2017-11-15       Impact factor: 4.030

Review 6.  Ion Channel Genes and Epilepsy: Functional Alteration, Pathogenic Potential, and Mechanism of Epilepsy.

Authors:  Feng Wei; Li-Min Yan; Tao Su; Na He; Zhi-Jian Lin; Jie Wang; Yi-Wu Shi; Yong-Hong Yi; Wei-Ping Liao
Journal:  Neurosci Bull       Date:  2017-05-09       Impact factor: 5.203

7.  Mapping genetic modifiers of survival in a mouse model of Dravet syndrome.

Authors:  A R Miller; N A Hawkins; C E McCollom; J A Kearney
Journal:  Genes Brain Behav       Date:  2013-11-14       Impact factor: 3.449

8.  De novo GABRG2 mutations associated with epileptic encephalopathies.

Authors:  Dingding Shen; Ciria C Hernandez; Wangzhen Shen; Ningning Hu; Annapurna Poduri; Beth Shiedley; Alex Rotenberg; Alexandre N Datta; Steffen Leiz; Steffi Patzer; Rainer Boor; Kerri Ramsey; Ethan Goldberg; Ingo Helbig; Xilma R Ortiz-Gonzalez; Johannes R Lemke; Eric D Marsh; Robert L Macdonald
Journal:  Brain       Date:  2016-11-17       Impact factor: 13.501

9.  Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function.

Authors:  Vaishali S Janve; Ciria C Hernandez; Kelienne M Verdier; Ningning Hu; Robert L Macdonald
Journal:  Ann Neurol       Date:  2016-05       Impact factor: 10.422

10.  Impaired surface αβγ GABA(A) receptor expression in familial epilepsy due to a GABRG2 frameshift mutation.

Authors:  Mengnan Tian; Davide Mei; Elena Freri; Ciria C Hernandez; Tiziana Granata; Wangzhen Shen; Robert L Macdonald; Renzo Guerrini
Journal:  Neurobiol Dis       Date:  2012-10-13       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.